
Cellbyte raises $2.75m to fund pharma drug launch platform
Esme Needham | November 27, 2025 | News story | Product launch | AI, Cellbyte, biotech
Cellbyte has announced that it has raised $2.75m in seed funding for the streamlining of pharmaceutical drug launches.
The complexity of steps such as pricing and reimbursement strategies, regulatory approval and data collection means that novel, life-saving drugs can take over a year to reach the patients who need them. Pharmaceutical companies often spend hundreds of thousands of dollars to access and complete market data in advance of a drug launch. Cellbyte’s AI-native platform, however, is designed to allow drug launch teams to rapidly analyse millions of data points. It aims to determine the most effective launch sequences and market strategies, reducing cost, time and labour.
Cellbyte’s goal is to replace outdated legacy databases, reducing data processes that previously took up to a year to a matter of minutes without loss of quality.
“I’ve seen countless innovations transforming clinical development. Yet in pricing and market access, decisions still too often rely on manual work and anecdotal evidence even though information is so abundant. Now, generative AI is changing that,” said Daniel Moreira, co-CEO and co-founder at Cellbyte.
Felix Steinbrenner, co-CEO and co-founder at Cellbyte, said: “The industry is ready to rethink drug launch workflows and adopt faster, higher quality and cost-effective processes.”
Related Content

Arkin Capital closes $100m fund for pre-clinical and early clinical-stage biotech
Arkin Capital has announced the closing of Arkin Bio Ventures III, a $100m fund designed …

Lilly opens fourth US Gateway Labs site
Eli Lilly has opened its newest Lilly Gateway Labs (LGL) site in San Diego, California, …

LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence
LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …





